Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).
Authors
Vaibhav Sahai
University of Michigan, Ann Arbor, MI
Vaibhav Sahai , Kent A. Griffith , Bruce Shih-Li Lin , Heloisa P. Soares , Sreenivasa R Chandana , Oxana V. Crysler , Thomas Enzler , Mark Zalupski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03785873
DOI
10.1200/JCO.2022.40.4_suppl.438
Abstract #
438
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2018 Gastrointestinal Cancers Symposium
Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies.
First Author: Smita Suhas Joshi
Poster
2014 ASCO Annual Meeting
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
First Author: Manish Sharma
Poster
2017 Gastrointestinal Cancers Symposium
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
First Author: Manish Sharma